Ionis Drug Spinraza Conquers Spinal Muscular Atrophy with Statistically Significant Results

Biogen (BIIB) and Ionis (IONS) announced that Spinraza (nusinersen), an antisense drug designed and developed by Ionis met its primary endpoint in Phase 3 trial of the CHERISH Study in later-onset spinal muscular atrophy (SMA). This was the second positive Phase 3 study that provides evidence of Spinraza’s efficacy and favorable safety. The data demonstrate statistically significant and clinically meaningful results.  

Children receiving Spinraza experienced a highly statistically significant improvement in motor function compared to those who did not receive treatment. Spinraza. There was a favorable safety profile . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.